Premarket Movers Oct 15, 2026: Why WETO, NCPL, DRMA Are Up

WETO — Wetour Robotics Ltd (+55.7%)

Wetour Robotics is up 55.7% in premarket trading, at $1.31, on 23,558,366 shares. That compares with a 20-day average of 6,522,329 for a full session, so premarket volume is already well above normal. Market cap is only about $69.0M.

The likeliest catalyst is the company's October 15 announcement, via GlobeNewswire, that it paused sales under its at-the-market (ATM) share program. An ATM lets a company sell new shares into the market over time, which can dilute holders. During the pause, Wetour won't start new sales. The agreement stays in place, and the company can resume sales later. The link is unconfirmed, though. No source explicitly ties the rally to the pause. One credited generic "robotics innovations," and other quotes showed declines (a Benzinga premarket report of −12.65% and a Yahoo quote of −14.81%). Treat the size of this move with caution.

The prior-day daily chart was weak. There was no pattern signal, RSI was 35, ADX was 4, and the moving-average stack was bearish. The stock sat 99.4% below its 52-week high, with a relative strength rating of 1 and conviction of 0/100 (grade D). The squeeze score is a low 12/100. Free float is 25.9%, short interest is 35,047 shares, and days to cover is 0.0. A short-sale restriction (SSR) is active, which limits short selling on a stock that has dropped sharply.

This is a bounce from deep lows in a tiny, dilution-prone name. It can reverse fast.

NCPL — Netcapital Inc. (+26.8%)

Netcapital is up 26.8% in premarket, at $1.99, on 11,659,149 shares against a 20-day average of 25,463,511. Market cap is about $12.3M. We also covered the stock's after-hours jump in yesterday's recap.

The most specific catalyst is not clean good news. Benzinga tied an 18.85% after-hours gain on October 14 to investors weighing a class action lawsuit and SEC allegations of revenue overstatement. Separately, on October 14 Netcapital announced it had regained compliance with Nasdaq's minimum bid price requirement. No source names a driver for the premarket move itself, so the link to these items is inferred, not confirmed. Filings from October 14 and September 25 were flagged as delisting-related.

The prior-day setup was strong. The moving-average stack was bullish, RSI was 60, ADX was 47, and the trend-template score was 5. Relative strength was 99 and conviction was 67/100 (grade B). The stock was 36.7% below its 52-week high, and the premarket gap is +33.5%. The squeeze score is 46/100. Free float is 46.9%, short interest is 1,651,407 shares, and days to cover is 0.0. It drew one mention on r/daytrading.

Legal and delisting overhangs make this a high-risk name.

DRMA — Dermata Therapeutics, Inc. (+24.8%)

Dermata is up 24.8% in premarket, at $0.77, on 46,028,339 shares. Its 20-day average is just 43,819, so volume is extreme relative to normal. Market cap is about $2.5M.

The catalyst appears to be Dermata's October 15 press release announcing positive topline results from a cosmetic study of its Tome Foundational Treatment. The study was small and open-label, with 31 participants using the product once weekly for four weeks. Of those, 93% agreed it was comparable to a professional in-office procedure and 90% agreed they saw more noticeable results than with other products. Sources don't confirm the full size of the move. Finviz showed +17.67% at 9:10 AM ET, and one tracker recorded a peak of +20.8%.

The prior-day chart was bearish: RSI 15, ADX 17, a bearish moving-average stack, and 85.8% below the 52-week high. Relative strength was 3 and conviction was 0/100 (grade D). Squeeze score is 17/100, free float is 76.7%, short interest is 167,251 shares, and days to cover is 1.2. SSR is active. A shelf (S-3) filing on October 9 means the company could sell shares.

An oversold bounce on a small open-label study in a micro-cap is fragile.

OPK — OPKO HEALTH, INC. (+22.3%)

OPKO Health is up 22.3% in premarket, at $1.67, on 21,404,368 shares. Its 20-day average is 2,087,196. It's the largest company on this list, with a market cap near $1.0B.

The likeliest catalyst is Labcorp's agreement to buy select assets of OPKO's BioReference Health subsidiary, announced October 15 at 8:02 AM ET. Seeking Alpha reported the deal at up to $872M. Reports of the premarket gain vary: RTTNews had +7.35%, while Benzinga's list had 22.6%. Deal terms come from news coverage only, since no company release or 8-K turned up.

The prior-day setup showed a piercing line candle, a possible reversal sign. RSI was 35, ADX was 33, and the moving-average stack was mixed. The stock was 21.1% below its 52-week high. Relative strength was 58, conviction was 62/100 (grade B), and the trend-template score was 6. The squeeze score is 51/100. Short interest is 34,558,372 shares, or 13.8 days to cover. That is how many days of average volume it would take shorts to buy back. Free float is 43.5%. Heavy short interest can amplify a news-driven jump, but it can also fade quickly. For more on gaps, see our gap fill strategy guide.

The bottom line

Premarket moves come on thin volume, and prices can shift sharply once the 9:30 AM ET open arrives. Three of these four are micro-caps with dilution, delisting or legal questions. Chasing extended gainers is high-risk, and patterns and squeezes often fail. Manage risk and do your own research. This is educational content, not advice.

StockSetups scans the full US universe after every close and every premarket morning. It looks for chart patterns, squeeze setups and trend strength.